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Patient characteristic Number (percentage) of
patients unless noted otherwise
APACHE II scorea 19.4 ± 7.5
SOFA scorea 9.2 ± 2.9













Failure 1 (5.5%)In the present study, we assessed urinary neutrophil
gelatinase-associated lipocalin (uNGAL) during 24-hour
continuous renal replacement therapy (CRRT) in critic-
ally ill patients. The study was performed in accordance
with the Declaration of Helsinki and was approved by
the Scientific Council and the Ethics Committee of
Evangelismos Hospital in Athens, Greece. Informed
consent was provided by family members of the
patients included in the study. Eighteen critically ill
patients (13 men and five women with a mean age of
69 ± 14 years) in an interdisciplinary intensive care unit
underwent continuous veno-venous hemodiafiltration
(CVVHD). Three had oliguria (urine output of less
than 200 mL per 12 hours). Patient characteristics at
enrollment are shown in Table 1.
uNGAL was determined before CRRT onset and at 6
and 24 hours during CVVHD. uNGAL was measured by
using a chemiluminescent assay with ARCHITECT tech-
nology (Abbott Diagnostics Inc., Abbott Park, IL, USA).
For CVVHD, pump-driven machines - from Prisma (a
brand of Gambro, Deerfield, IL, USA), Kimal (Dormagen,
Germany), or Nephro-Tech (Shawnee, KS, USA) - were
used with a 0.9 m2 polysulfone filter. uNGAL levels did
not change, whereas serum creatinine and serum cystatin
C significantly decreased (Table 2). No correlation was
found between uNGAL levels and the illness severity
scores at inclusion.
In a study by Schilder and colleagues [1] in a previous
issue of Critical Care, plasma NGAL (pNGAL) in critically
ill patients was similarly not affected by RRT. No net
removal of pNGAL was established, although absorption
by the filter with concomitant production could not be* Correspondence: a.icusn@gmail.com
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unless otherwise stated.definitively excluded. Besides an insufficient clearance
through the filter, other causes could be implicated for
the remaining NGAL levels.
Whereas pNGAL can come from an extra-renal source
(as in sepsis [2]), uNGAL may derive mostly from local
synthesis in the kidney [3]. NGAL that has been synthe-
sized in the kidney and can be detected in urine may not
efficiently enter the systemic circulation to be cleared by
the filter.Diabetes 6 (33%)
Vasopressors 11 (61%)
aValues are expressed as mean ± standard deviation. APACHE II, Acute
Physiology and Chronic Health Evaluation II; RIFLE, risk, injury, failure, loss,
end-stage; SAPS, Simplified Acute Physiology Score; SIRS, Systemic Inflammatory
Response Syndrome; SOFA, Sequential Organ Failure Assessment.
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Table 2 Renal function biomarkers during continuous
renal replacement therapy
Before CRRT At 6 hours At 24 hours P value
uNGAL, ng/mL 1,917 ± 1,911 1,675 ± 1,634 1,661 ± 1,633 0.23
sCr, mg/dL 2.8 ± 1.5 2.3 ± 0.9 1.9 ± 0.9 <0.0001
sCysC, mg/L 2.74 ± 0.8 1.97 ± 0.64 1.90 ± 0.8 <0.0001
CRRT, continuous renal replacement therapy; sCr, serum creatinine; sCysC,
serum cystatin C; uNGAL, urinary neutrophil gelatinase-associated lipocalin.
Vasileiadis et al. Critical Care  (2015) 19:140 Page 2 of 2Another possible explanation concerns the significance
of NGAL function. It has been shown that NGAL has
some physiological functions such as carrying out anti-
microbial activity and a protective role in the kidney [4,5].
Substituting the function of the kidney with the artifi-
cial filter does not mean that the reasons leading to the
increased levels of NGAL are eliminated (for example,
sepsis or, specifically for the uNGAL, the kidney damage).
So regardless of the possibility that the filter cleanses
the factor, the production of NGAL might be purposely
preserved to carry out its physiological role.
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